Pharmacists' Answer to the COVID-19 Pandemic: Contribution of the Federal Retail Pharmacy Program to COVID-19 vaccination across Sociodemographic Characteristics-United States.

Background: The Federal Retail Pharmacy Program (FRPP) integrated pharmacies as partners in the national effort to maximize vaccination during the COVID-19 public health emergency.

Objective: The objective of this study was to quantify the contribution of pharmacies participating in FRPP to COVID-19 vaccination efforts during December 2020-September 2023 across sociodemographic groups in the United States.

Methods: Data on COVID-19 vaccine doses administered reported to Centers for Disease Control and Prevention by FRPP and jurisdictional immunization information systems of all 50 states, the District of Columbia, and U.

Vaccines against mpox: MVA-BN and LC16m8.

Introduction: Global outbreaks involving mpox clade IIb began in mid-2022. Today, clade IIb and clade I outbreaks continue. Reliable mpox vaccines can prevent serious mpox disease and death.

Pharmacist assessments and care to improve adult vaccination rates: A report from project IMPACT vaccine confidence.

Background: Neglect of vaccination needs among adults results in a needless burden of hospitalization, suffering, and death. America's community pharmacists deliver a substantial portion of adult vaccinations, yet many Americans still have unmet vaccination needs.

Objectives: This study evaluated rates of vaccine contraindications, acceptance, and willingness to be vaccinated among ambulatory adults.

Effect of an Innovative Immunization Practice Model to Improve Population Health: Results of the Project IMPACT Immunizations Scaled Demonstration.

U.S. adult vaccination rates remain low.

Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.

Seasonal variation in influenza vaccine effectiveness (VE) makes real-world evidence (RWE) useful in supplementing the clinical-evidence base from randomized clinical trials. Adjuvanted inactivated influenza vaccine (aIIV) VE has been evaluated in multiple nonrandomized RWE studies. A systematic literature review of RWE studies evaluating the absolute or relative VE of aIIV was conducted.